Navigation Links
Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
Date:11/1/2012

he central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

Forward-Looking Statements
This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, Omeros' expectations regarding when it will announce data from its Phase 1 clinical trial evaluating OMS824 as well as its two ongoing Phase 3 clinical programs; the number of preclinical programs that may enter the clinic in 2013; and that Omeros may have capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2012. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking stat
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
2. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
3. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
4. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
5. MiMedx Group Announces Record Third Quarter Results And Raises Revenue Estimates For The Year
6. IntelliCell BioSciences Announces Myron Z. Holubiak Joins the IntelliCell BioSciences Board of Directors
7. Synthetic Biologics Announces $10.8 Million Financing
8. Haemonetics Reports Second Quarter Fiscal 2013 Revenue Up 22%, Organic Revenue Up 6% and Adjusted EPS of $0.90, Reaffirms Fiscal 2013 Guidance and Announces Two-For-One Stock Split
9. Altogen Labs Announces Patent Filing for Bioremediation Process and Oil Spill Cleanup Products
10. Techne Corporation Declares Dividend And Announces An Increase In Its Share Repurchase Program
11. Law Office of Brodsky & Smith, LLC Announces Investigation of Complete Genomics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013 The new Public-Private Partnership (PPP) ... the association’s recent annual meeting drew praise from community ... Kroes, who called the action “a huge step forward ... to European innovation.” , The Board of Stakeholders voted ... Photonics PPP at its 29 April meeting in Brussels, ...
(Date:5/17/2013)... International, Inc. (NASDAQ: YONG ) ("Yongye" or ... crop nutrient products in the People,s Republic ... 16, 2013, the special committee (the "Special Committee") of ... provided a letter (the "Letter") issued by Abax Global ... to Full Alliance International Limited ("Full Alliance"). The Letter, ...
(Date:5/17/2013)... 17, 2013 The paradigm of ‘one ... systems that can help predict the adverse and therapeutic ... Stepaniants, Head of Computational Biology at the Genomics Laboratory, ... to ensure high-quality genomics when used as part of ... to complex data sets to identify key clinical targets ...
(Date:5/17/2013)... Tooth decay is an epidemic in American children with 50% ... World Health Organization says that worldwide, 60–90% of ... are the long-term effects of this transmissible infection? , ... oral bacterial imbalance and serious systemic issues like heart disease. ... also 100% preventable? Answer: there has been no way to ...
Breaking Biology Technology:SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3Yongye International Provides Update on Status of Proposed Go Private Offer 2Yongye International Provides Update on Status of Proposed Go Private Offer 3Yongye International Provides Update on Status of Proposed Go Private Offer 4Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3
... Milestones, CRANBURY, N.J., Nov. 3 Amicus Therapeutics,(Nasdaq: ... third quarter of,2008. On a reported basis calculated in ... a net loss,attributable to common stockholders of $0.36 per ... three months ended September 30, 2008. As of,September 30, ...
... Nov. 3 Biomoda, Inc. (OTC,Bulletin Board: BMOD) ... announced today that BUYINS.NET, http://www.buyins.net, is initiating ... data to October 2008. From November 2006 to ... BMOD have traded,for a total dollar value of ...
... and GUELPH, Ontario, Nov. 3 LI-COR,Biosciences ... agreement to,distribute LI-COR biotechnology products in Canada ... local presence of Mandel Scientific skilled staff, ... enhance our ability to serve,our Canadian customers," ...
Cached Biology Technology:Amicus Therapeutics Announces Third Quarter 2008 Financial Results 2Amicus Therapeutics Announces Third Quarter 2008 Financial Results 3Amicus Therapeutics Announces Third Quarter 2008 Financial Results 4Amicus Therapeutics Announces Third Quarter 2008 Financial Results 5Amicus Therapeutics Announces Third Quarter 2008 Financial Results 6Amicus Therapeutics Announces Third Quarter 2008 Financial Results 7Amicus Therapeutics Announces Third Quarter 2008 Financial Results 8Amicus Therapeutics Announces Third Quarter 2008 Financial Results 9Amicus Therapeutics Announces Third Quarter 2008 Financial Results 10Amicus Therapeutics Announces Third Quarter 2008 Financial Results 11Biomoda, Inc. (BMOD) SqueezeTrigger Price is $0.27. Approximately 1 Million Shares Shorted Since November 2006 According to Buyins.net Research Report 2Biomoda, Inc. (BMOD) SqueezeTrigger Price is $0.27. Approximately 1 Million Shares Shorted Since November 2006 According to Buyins.net Research Report 3Biomoda, Inc. (BMOD) SqueezeTrigger Price is $0.27. Approximately 1 Million Shares Shorted Since November 2006 According to Buyins.net Research Report 4LI-COR Biosciences and Mandel Scientific Company Inc. Announce Distribution Agreement 2
(Date:5/17/2013)... The AGA Research Foundation announced a new grant ... the gut microbiota, one of today,s most exciting areas ... The AGA Research Awards Panel selected Andrew T. Chan, ... and Harvard Medical School, Boston, as the 2013 AGA-Elsevier ... receive $25,000 of funding, commencing in July 2013, to ...
(Date:5/17/2013)... May 17, 2013, Shenzhen, China---- Why Tibetan antelope ... Qinghai-Tibetan Plateau? In a collaborative research published in ... BGI, and other institutes provide evidence that some ... adaption to harsh highland environments. The data in ... specific genetic mechanisms and the biology of other ...
(Date:5/16/2013)... a commitment to the support of underrepresented minority ... Foundation has announced the inaugural AGA Investing in ... by the National Institute of Diabetes and Digestive ... underrepresented minority students to further their research careers ... establishing this new award, AGA demonstrates its commitment ...
Breaking Biology News(10 mins):New gut microbiome research to explore red meat -- colorectal cancer pathway 2The genome sequence of Tibetan antelope sheds new light on high-altitude adaptation 2Underrepresented minority students receive fellowships in digestive disease and nutrition research 2
... at Schepens Eye Research Institute, an affiliate of Harvard ... inside blood vessel cells that controls angiogenesis (new blood ... and off by the balance between two enzymes (known ... of the same lipid membrane to fulfill opposite missions, ...
... Institutes of Health today provided the clearest picture yet of ... genes associated with an increased risk of breast cancer. The ... 2 (BRCA2). In addition, the study identified key predictors for ... mutations. , Each year, approximately 200,000 women in the ...
... a Saint Louis University vaccine researcher scrutinizes what in ... available anthrax vaccine. , This new type of anthrax ... according to peer-reviewed research published in Vaccine . ... given to 100 volunteers at four sites around the ...
Cached Biology News:Schepens scientists are first to discover angiogenesis switch inside blood vessel cells 2Schepens scientists are first to discover angiogenesis switch inside blood vessel cells 3New findings offer more complete view of breast cancer gene mutations in US population 2New findings offer more complete view of breast cancer gene mutations in US population 3
... Thermo's orbital shaker stands ... a more ergonomic height, and ... Purpose-built from welded tubular steel, ... to support the weight and ...
... 5'G AATTC3' 3'CTTAA G5' Inactivation Conditions: Heat inactivation ... Storage Conditions: 10mM Tris-HCl (pH 7.5), 100mM KCl, ... BSA, 50% glycerol. Shipping and Storage: Shipped on ... unit is defined as the amount of enzyme ...
... experiment based analysis package designed with easy ... and powerful functionality., Image acquisition interface is ... easy image capture. Sequential and dynamic ... Saturation Warning Single ...
... stainless-steel shaker flask clips, purpose-designed to firmly ... All clips are equipped with a top ... include a bottom retainer spring, and silicon ... expensive glassware. Clips include the required ...
Biology Products: